India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (OGN), the U.S.-based women's healthcare company that could reshape the landscape of global pharma dealmaking.

According to people familiar with the matter cited by The Economic Times, Sun Pharma has already submitted a non-binding all-cash bid and lined up $10-14 billion in acquisition financing. That's not exactly window shopping—this is serious money for what would become the largest cross-border transaction ever undertaken by an Indian drugmaker.

What Makes This Deal Transformative

If the transaction closes, we're looking at a deal valued at roughly $10 billion including debt. That would make it Sun Pharma's largest acquisition to date and its boldest overseas expansion since the Ranbaxy deal. The strategic logic is clear: significantly strengthen its presence in women's health biopharma and biosimilars while getting a much bigger footprint in the lucrative U.S. market.

One source described the potential deal as "transformative," noting it would substantially bolster Sun Pharma's presence in the U.S. market, according to News18.

People cited by ET said Sun Pharma has brought in a European bank as an adviser to prepare a financial proposal for Organon's board. But let's be clear—talks are still preliminary, and there's no guarantee negotiations will actually result in a transaction. This is the part where everyone involved gets to say "no comment" while frantically working behind the scenes.

Organon's Journey and Strategic Position

Organon was spun off from Merck & Co. (MRK) in 2021, inheriting roughly $9.5 billion in debt as part of the separation. Since then, the company has been pursuing a dual strategy: inorganic growth through acquisitions while simultaneously trying to streamline its balance sheet through asset sales. It's the corporate equivalent of trying to build muscle and lose weight at the same time.

Another media report confirmed that Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal for the deal.

In September 2024, Organon acquired Dermavant from Roivant Sciences (ROIV) for $1.2 billion, adding innovative dermatologic therapies to its portfolio. More recently, it sold its JADA post-partum hemorrhage system to Laborie Medical for $465 million as part of its ongoing divestment of non-core assets.

As of the end of the second quarter of fiscal 2025, Organon's debt stood at $8.9 billion—still substantial, but headed in the right direction.

The Valuation Dance

Here's where it gets interesting: ET reported that Sun Pharma re-engaged in talks after Organon's share price roughly halved, having earlier paused discussions due to valuation concerns. Nothing focuses the mind quite like a 50% discount.

It remains unclear whether Sun Pharma would pursue an all-cash offer or opt for a mix of cash and stock. People familiar with the matter emphasized that negotiations may not lead to a deal and that a bidding war is also possible. If the transaction does close, the combined entity would have pro forma leverage of about 2.5 times net debt to EBITDA—manageable, but not exactly light.

Organon's Recent Performance

Organon reported third-quarter adjusted earnings of $1.01 per share, beating the consensus estimate of 94 cents. Sales increased 1% to $1.60 billion, surpassing the consensus of $1.58 billion.

However, Organon lowered its fiscal 2025 sales guidance from $6.275 billion-$6.375 billion to $6.20 billion-$6.25 billion, falling below the consensus of $6.289 billion. That guidance cut suggests the company is navigating some headwinds despite the earnings beat.

Nexplanon, a contraceptive implant, is the company's top-selling biopharma product and represents a key asset in any potential deal.

FDA Approval Adds Strategic Value

On Friday, the U.S. Food and Drug Administration approved a supplemental New Drug Application for Nexplanon (etonogestrel implant), extending the duration of use from three years to up to five years. That's a meaningful improvement in convenience for patients and potentially expands the product's market appeal.

The approval also includes a new Risk Evaluation and Mitigation Strategy (REMS) program in the U.S. designed to mitigate complications due to improper insertion and removal of the device.

OGN Price Action: Organon shares were up 4.68% at $9.17 at the time of publication on Tuesday, according to market data.